Scholar Rock Holding Corporation $SRRK Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 60.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 361,453 shares of the company’s stock after selling 549,622 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Scholar Rock were worth $17,416,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Allworth Financial LP purchased a new position in Scholar Rock in the second quarter valued at about $35,000. PNC Financial Services Group Inc. raised its stake in shares of Scholar Rock by 92.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company’s stock worth $62,000 after buying an additional 610 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Scholar Rock by 219.0% during the 3rd quarter. IFP Advisors Inc now owns 1,560 shares of the company’s stock worth $75,000 after buying an additional 1,071 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 20.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after buying an additional 242 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in Scholar Rock during the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SRRK. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 price target on shares of Scholar Rock in a report on Monday, September 21st. Jefferies Financial Group raised their price target on Scholar Rock from $57.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Piper Sandler increased their price objective on Scholar Rock from $60.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, September 15th. TD Cowen reiterated a “buy” rating on shares of Scholar Rock in a research report on Monday, September 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.67.

Trending Headlines about Scholar Rock

These are some of the SRRK headlines that stood out recently:

• Positive Sentiment: HC Wainwright raised its Q4 2026 and FY2026 EPS estimates slightly, while maintaining a Buy rating and $70 price target. Scholar Rock analyst estimates
• Negative Sentiment: Wolfe Research cut its rating on SRRK from Outperform to Peer Perform, removing a bullish endorsement and potentially contributing to near-term selling pressure. Wolfe Research ratings
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for FY2027–FY2030, including cutting FY2029 from a profit estimate to a loss and reducing projected FY2030 EPS from $1.44 to $1.00. Those reductions temper the longer-term outlook despite the firm’s Buy rating and $70 target. Scholar Rock analyst estimates

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Srinivas Akkaraju bought 146,970 shares of the business’s stock in a transaction dated Monday, October 26th. The shares were acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the purchase, the director owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. The trade was a 2.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.30% of the stock is currently owned by corporate insiders.

Scholar Rock Stock Down 7.4%

Shares of SRRK opened at $43.16 on Friday. The firm has a market cap of $5.27 billion, a PE ratio of -12.85 and a beta of 0.78. The company’s fifty day moving average is $46.38 and its two-hundred day moving average is $48.22. Scholar Rock Holding Corporation has a fifty-two week low of $29.35 and a fifty-two week high of $61.76. The company has a quick ratio of 7.02, a current ratio of 5.41 and a debt-to-equity ratio of 1.16.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.30 million. During the same period last year, the business posted ($0.90) earnings per share. Analysts forecast that Scholar Rock Holding Corporation will post -3.11 earnings per share for the current year.

Scholar Rock Company Profile

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.